Table 3 Generalized estimating equation models predicting SLEDAI-2K with CMV infection, anti-CMV treatment and pp65 titers during follow-up
Outcome: SLEDAI-2K | Beta coefficient (95%CI) | P value |
|---|---|---|
Model 1: CMV vs. No CMV over time | ||
 Time | -0.08(-0.11;-0.04) | <0.001 |
 No CMV | 1(ref) | ref |
 CMV | 1.88(0.64;3.13) | 0.003 |
 No CMV*Time | 1(ref) | ref |
 CMV*Time | -0.01(-0.05;0.04) | 0.817 |
Model 2: Anti-CMV treatment vs. No treatment over time | ||
 Time | -0.07(-0.09;-0.05) | <0.001 |
 No Treatment | 1(ref) | ref |
 Treatment | -1.50(-2.97;-0.02) | 0.046 |
 No Treatment*Time | 1(ref) | ref |
 Treatment*Time | -0.06(-0.10;-0.02) | 0.001 |
Model 3: pp65 | ||
 pp65 | 0.14(0.09;0.18) | <0.001 |